e-therapeutics PLC's (LON:ETX) CEO Ali Mortazavi talks to Proactive London about their six months results and successful lab testing of its lead technology.
He details further progress on its RNAi Platform with results from characterisation benchmarking studies now successfully completed.
The research demonstrated e-Therapeutics’ approach was equivalent in performance to leading competitor programmes showing 'deep and durable target gene knock-down'.
In a separate announcement, e-Therapeutics released its interim results, which charted the company’s significant operational progress in the six months ended July 31 and beyond and, crucially, showed the business was in a financially stable position to kick on.